Terry Myerson

@Truveta CEO and co-founder. Saving Lives with Data.

[Terry Myerson @tmyerson]

We just posted our first Instagram Reel at @Truveta, and I love it.

We’re bringing insights directly to people where they already are. And personally, I love that it’s about soccer. Go Team USA (@USMNT). Go @SoundersFC.

Follow us on Instagram: https://t.co/ue1NQGeBA6

[Terry Myerson @tmyerson]

Let’s ask better questions:
Are teens getting the care they need for depression?
Which interventions are reversing pre-diabetes?
What’s actually working for kids struggling with weight?

[Terry Myerson @tmyerson]

Food allergies in kids rose 88% between 1997 and 2018.

[Terry Myerson @tmyerson]

We are humbled that @truveta is nominated as a finalist for two annual @geekwire awards: Deal of the Year and Next Tech Titan. On behalf of our entire team and our incredible health system members, please join us in Saving Lives with Data by voting here: https://t.co/b24QPe1N2P

[CNBC's Fast Money @CNBCFastMoney]

A new study found that patients without type 2 diabetes are more likely to discontinue treatment of GLP-1 drugs, with other factors like income, drug side effects playing a role.

@truveta lead study author Tricia Rodriguez shares findings:
https://t.co/ELhoBvhkmG

[Truveta @truveta]

Exciting breakthroughs in healthcare are on the horizon with the #TruvetaGenomeProject. Combining genomic + medical data, we’re unlocking the potential for targeted therapies and better medicines for Alzheimer's, autoimmune disorders, psychiatric diseases & more.

[Truveta @truveta]

Via @statnews

"Health data company Truveta said Monday it’s partnering with health systems and drugmakers to launch the #TruvetaGenomeProject, a database of genetic data that is expected to accelerate personalized medicine and help discover new drugs."
https://t.co/kBBDhZX20M

[Truveta @truveta]

Introducing the #TruvetaGenomeProject: The world's largest and most diverse genomic + phenotypic database ever assembled.

Today, 30 leading US health systems, Truveta, Regeneron Genetics Center & Illumina announce a bold vision to transform how diseases are prevented, diagnosed, and cured.

[Terry Myerson @tmyerson]

Starting today, with the help of AI and collaboration with health system partners, we’re creating the largest database of clinical and genetic data ever assembled. https://t.co/EDoc5pbTVw

[Terry Myerson @tmyerson]

Big news from @Truveta: We're launching the #TruvetaGenomeProject!

Since 2020, we've built a dataset of 120M de-identified patient records, updated daily. But there’s a missing piece: understanding the biology behind health outcomes – our genetic code.

[Terry Myerson @tmyerson]

Amazing how this SURMOUNT-5 clinical trial aligns with @truveta Research’s real-world data study within confidence ranges… for probably 1% of the time and cost.

[Truveta @truveta]

New results released today from the SURMOUNT-5 study on GLP-1s aligned with Truveta Research's earlier findings, which were published in @JAMAInternalMed five months ago and included 20x the patients (18.4K vs. 751). Both studies focus on the comparative effectiveness of #tirzepatide (#Mounjaro) vs. #semaglutide (#Ozempic) for weight loss.

Learn more about Truveta Research's study: https://t.co/huhvCHYkqb

[Terry Myerson @tmyerson]

Be sure to join for our webinar tomorrow, where @bostonsci’s Dr. Michael R. Jaff will share the advantages of real-world EHR data in device development, along with our CMO @RyanAhernMD. It’s going to be a great discussion – you won’t want to miss it. https://t.co/vY9EhmAd01

[Terry Myerson @tmyerson]

It's been terrific to see researchers putting @truveta's mother-child data to work. It’s crazy to me how many studies still rely on claims data to guess mom-child links via billing events that exclude Medicaid or uninsured patients, introducing bias. Linking directly through birth data in the EHR is a game-changer for accuracy and equity.

[Terry Myerson @tmyerson]

Hope everyone is enjoying a great holiday break with family and friends!

[Truveta @truveta]

Wishing everyone a happy and healthy Thanksgiving! 🦃

[Terry Myerson @tmyerson]

As I read concerns regarding new US public health leadership, I reflect that transparency in data is essential to earning trust in science - but I'm reminded that Nobel Laureate Ronald Coase once said, "If you torture data long enough, it will confess to anything," while Mark Twain famously quipped, "There are lies, damned lies, and statistics."

While these quotes highlight the risks of misusing data, I think transparency is the antidote to skepticism in science. By making data accessible and methods clear, we can strengthen the foundation of trust in scientific discovery.

[Terry Myerson @tmyerson]

I tend to be a critic of the delays, opacity, and cost of the peer reviewed journal process – but this kind of transparent thoughtful debate on articles once published is terrific. Thanks to @JAMAInternalMed for facilitating this important dialogue on a meaningful @truveta Data study. https://t.co/wEBiRQ0IOp

[Truveta @truveta]

Truveta Research et al recently co-authored a study published in JAMA Internal Medicine on the comparative effectiveness between tirzepatide and semaglutide for weight loss, which has been the most-viewed study on JAMA IM since its publication in early July.

Another set of researchers responded to the study with questions on methodology - namely related to the study's use of real-world data. Study co-authors from Truveta Research, Nick Stucky and Tricia Rodriguez, PhD, MPH, along with Providence Medical Director Ty J. Gluckman, FACC, FAHA, penned a response to the inquiry, in a letter that was published today in JAMA IM.

Flip through for a summary of their response, or view the full letter here: https://t.co/zpz7uXVlEV

Learn more about the study here: https://t.co/7ZjGXlKVHc